Posted by Michael Wonder on 31 Oct 2019
NICE terminates another two assessments for cancer medicines
30 October 2019 - One medicine is from Janssen; the other is from Eli Lilly.
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults because Janssen did not provide an evidence submission.
NICE is also unable to make a recommendation on ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma in adults who have had sorafenib, because Lilly did not provide an evidence submission.
